Framtidig behandling av akutt myelogen leukemi - (i) effekt av ny molekylært målretta terapi og (ii) cytokinprofilar som eit klinisk verktøy for oppfølging etter antileukemisk terapi
- Prosjektnummer
- 911788
- Ansvarlig person
- Øystein Bruserud
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Blood
- Forskningsaktivitet
- 5. Treatment Developement
Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome.
Dis Markers 2015;2015():943430. Epub 2015 nov 2
PMID: 26609191
The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells.
Stem Cell Res 2015 Nov;15(3):530-41. Epub 2015 sep 25
PMID: 26468600
Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Eur J Haematol 2016 Mar;96(3):211-21. Epub 2015 nov 26
PMID: 26465810
Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.
BMC Pharmacol Toxicol 2015;16():12. Epub 2015 mai 2
PMID: 25934555
Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.
Expert Rev Hematol 2015 Jun;8(3):315-27. Epub 2015 apr 22
PMID: 25901742
Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis.
Thromb Res 2015 Jul;136(1):30-9. Epub 2015 apr 11
PMID: 25895848
Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.
Expert Rev Hematol 2015 Jun;8(3):299-313. Epub 2015 apr 3
PMID: 25835070
The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers--a comparative study of serum versus plasma samples.
J Immunol Methods 2015 Mar;418():19-28. Epub 2015 jan 28
PMID: 25637409
Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.
Oncotarget 2015 Feb 20;6(5):2794-811.
PMID: 25605239
Connexin expression in human acute myeloid leukemia cells: identification of patient subsets based on protein and global gene expression profiles.
Int J Mol Med 2015 Mar;35(3):645-52. Epub 2014 des 19
PMID: 25529637
Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells.
Oncoscience 2014;1(8):529-39. Epub 2014 aug 6
PMID: 25594060
Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.
Molecules 2014;19(11):18414-47. Epub 2014 nov 12
PMID: 25397735
Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation.
J Transplant 2014;2014():404096. Epub 2014 okt 8
PMID: 25374676
Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis.
Springerplus 2014;3():571. Epub 2014 sep 30
PMID: 25332871
SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute Myeloid Leukemia stem cells.
Cell Stem Cell 2014 Oct 2;15(4):431-46.
PMID: 25280219
Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells.
Expert Opin Ther Targets 2014 Nov;18(11):1237-51. Epub 2014 sep 9
PMID: 25200484
Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.
Proteomics 2014 Sep;14(17-18):1971-6. Epub 2014 aug 8
PMID: 25044641
Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?
Expert Opin Ther Targets 2014 Aug;18(8):929-44. Epub 2014 jun 24
PMID: 24956934
Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
Mol Cancer 2014;13():116. Epub 2014 mai 21
PMID: 24885082
In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells.
Leuk Res Treatment 2014;2014():143479. Epub 2014 jan 8
PMID: 24527217
Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.
Br J Haematol 2014 Jan;164(2):200-11. Epub 2013 okt 23
PMID: 24383842
Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.
Cell Prolif 2013 Oct;46(5):554-62.
PMID: 24073609
CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.
Oncotarget 2013 Sep;4(9):1438-48.
PMID: 23988457
Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.
Oncotarget 2013 Jun;4(6):830-43.
PMID: 23919981
Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia.
Transfus Med 2013 Dec;23(6):397-406. Epub 2013 aug 6
PMID: 23919332
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.
Clin Epigenetics 2013;5(1):13. Epub 2013 aug 1
PMID: 23915396
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.
Clin Epigenetics 2013;5(1):12. Epub 2013 jul 30
PMID: 23898968
Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine.
BMC Pharmacol Toxicol 2013;14():35. Epub 2013 jul 11
PMID: 23845085
Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma.
Cytotherapy 2013 Jul;15(7):850-60. Epub 2013 apr 24
PMID: 23623276
Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
Expert Opin Investig Drugs 2013 May;22(5):551-63.
PMID: 23586877
Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.
Cell Death Dis 2013;4():e516. Epub 2013 feb 28
PMID: 23449452
The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.
Toxins (Basel) 2013 Feb;5(2):336-62. Epub 2013 feb 18
PMID: 23430540
Iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from Streptosporangium sp. induces apoptosis selectively in myeloid leukemia cell lines and patient cells.
Mar Drugs 2013;11(2):332-49. Epub 2013 jan 30
PMID: 23364682
Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
Blood 2013 Feb 14;121(7):e34-42. Epub 2012 des 12
PMID: 23243270
Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
Curr Cancer Drug Targets 2013 Jan;13(1):30-47.
PMID: 22873213
Anticancer Immunotherapy in Combination with Proapoptotic Therapy - Possible Therapeutic Strategies for Enhancement of Anticance
Advances in Cancer Drug Targets 2013; 1: 172-206
Disease-stabilizing treatment of human acute myeloid leukemia - experimental and clinical studies.
- Disputert:
- januar 2013
- Hovedveileder:
- Øystein Bruserud
- Karen Marie Hagen Prosjektdeltaker
- Kristin Paulsen Prosjektdeltaker
- Kimberley Joanne Hatfield Postdoktor
- Håkon Reikvam Prosjektdeltaker
- Annette Brenner Postdoktor
- Knut Anders Mosevoll Ph.d.-kandidat
- Guro Kristin Melve Ph.d.-kandidat
- Ina Merethe Styrmoe Ph.d.-kandidat
- Tor Henrik Anderson Tvedt Ph.d.-kandidat
- Øystein Bruserud Prosjektleder
- Fredric G Pascal Pendino Leder av forskningsgruppe
- Ina Nepstad Ph.d.-kandidat
- Jerome Tambourin Leder av forskningsgruppe
- Stein Ove Døskeland Leder av forskningsgruppe
- Kristin Paulsen Rye Prosjektdeltaker
- Astrid Olsnes Kittang Postdoktor
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest